'srk: aaron kirtchfeld managing editor of bloomberg dales for bloomberg news. we have been here from the beginning. when sancho, chemchina. -- monsanto, chemchina. it is trading below the price. what does it tell us? completion risk. we are looking at a chinese state backed entity buying a european company which has operations in the u.s.. chinese dealse for companies that operate in the u.s. there's always the big question of what does the u.s. government do? mark: foreign investment. >> exactly. it is very scary for chinese companies because they take a look and ask themselves, does this have an impact on our food supply in the u.s.? a lot of people are wondering, will the u.s. use this as a political to block the deal. mark: why did syngenta settle for chemchina and not monsanto? >> money talks. chemchina offered $43 billion in cash. offeranta -- monsanto's was cash and stock. there was no way they would get regulatory approval. whereas with chemchina there is much less overlap. maybe a few minor disposals, but they're not expecting a big headache when it co